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Genetically engineered T-cells that express chimeric anti-
gen receptors (CARs) to directly target tumor-expressed
antigens have shown remarkable activity in clinical trials
for hematologic malignancies, but remain unproven for
the treatment of solid tumors. We find that in addition
to its well known high expression in neuroblastoma, the
disialoganglioside GD2 is also highly expressed on pedia-
tric sarcomas. Some human sarcoma cell lines have GD2
expression levels equivalent to that of the prototypical
neuroblastoma cell line LAN5, and immunohistochem-
ical staining of primary human tumor tissue samples
taken from essentially all patients with metastatic
osteosarcoma and a subset of patients with alveolar
rhabdomyosarcoma demonstrate robust expression of
GD2 on the cell surface. Based on these results, we have
developed models to test the ability of GD2-CAR T-cells
to target and lyse human sarcomas in vitro and in vivo.
We find that GD2-CAR modified T-cells induce specific
lysis of GD2-expressing solid tumors in vitro even at
effector:target ratios as low as 1:1, but fail to induce a
significant response in vivo using the same human cell
lines. Interestingly, we discovered that the pediatric sar-
coma xenografts induce a large expansion of murine
CD11b+Gr1+ myeloid-derived suppressor cells (MDSC)
that inhibit human T-cell responses in vitro. These
results lead us to adopt a combinatorial therapeutic
strategy in which we first neutralized the suppressive
potential of MDSC by administration of all-trans retinoic
acid (ATRA) followed by GD2-CAR therapy. This combi-
natorial approach results in significant improvements in
both overall survival and tumor growth. Given that
retinoids are already available in the clinic, these results
suggest that the effectiveness of CAR T-cell therapy for
solid tumors could be enhanced by coadministration of
retinoids to modulate the myeloid derived suppressor cells.
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